Russian biotechnology company PROMOMED has officially announced the start of its expansion into the pharmaceutical market of Uzbekistan. According to the company’s press service, the production site — the Biokhimik plant — has received a Good Manufacturing Practice (GMP) certificate from the Ministry of Health of the Republic of Uzbekistan.
Audit and Compliance Confirmation
The issuance of the permit document was preceded by a large-scale audit of production facilities. Inspectors from the Ministry of Health of Uzbekistan conducted a comprehensive inspection of the plant’s technical equipment, quality control system, and personnel qualifications. A key factor in the successful certification was the plant’s operating model, organized on a full-cycle principle: from the synthesis of the active pharmaceutical ingredient (API) in its own R&D center to the release of the finished dosage form.
The issued certificate confirms the compliance of Russian production with international standards and opens a “green corridor” for the export of medicinal products.
Focus on Endocrinology
At the first stage of expansion, PROMOMED will focus on the supply of drugs for the therapy of metabolic disorders. The company plans to export flagship products for the treatment of diabetes mellitus and obesity to the republic:
- Tyrzetta® (tirzepatide);
- Velgia Eco®.
The manufacturer emphasizes the technological advantage of these dosage forms: they are produced without the use of preservatives (phenol and benzyl alcohol), which increases the safety profile of the therapy.
“We expect that our presence will allow us to meet the needs of the healthcare system of Uzbekistan in key therapeutic areas. Our goal is to provide patients with modern drugs for the therapy of obesity, type 2 diabetes, oncological diseases, as well as for fighting infections.”
— Alisher Zakirov, Head of PROMOMED Group Representation in Uzbekistan
Market Potential
The choice of the therapeutic profile is driven by the explosive growth in demand for weight management and diabetes treatment drugs in the region. According to IQVIA analytical data, the Uzbekistan market dynamics show the following results:
| Market Segment | Growth Dynamics (2023–2025) |
|---|---|
| Total Pharma Market Growth (Value) | +23% (in 2025) |
| Obesity and Diabetes Drugs (Value) | +112% (CAGR) |
| Obesity and Diabetes Drugs (Volume/Packs) | +57% (CAGR) |
Development Strategy
The company’s long-term strategy provides for the registration of a broad portfolio in Uzbekistan, including more than 20 items. In addition to the endocrinology line, supplies of drugs for the treatment of oncological diseases, cardiovascular pathologies, and modern antibacterial agents are planned.
